胆汁酸受体TGR5与消化道恶性肿瘤的研究进展

摘要/Abstract

摘要： 消化道恶性肿瘤是常见的恶性肿瘤之一，目前发病率较高，死亡率亦较高，给全球带来的医疗负担越来越重，因此，寻求预防与治疗的新方法具有重要的意义。TGR5是第一个被证实的G蛋白偶联胆汁酸受体，基因表达分布广泛，包括内分泌腺、脂肪细胞、肌肉、免疫器官、脊髓和肠神经系统，TGR5信号通路可以参与调节葡萄糖代谢和能量代谢、抑制炎性反应和调节细胞增殖等，可能成为预防和治疗消化道肿瘤的新靶点。本文主要讨论了TGR5在代谢、炎性反应和细胞增殖方面的最新进展，并阐述其对消化道肿瘤发生发展的影响以及治疗潜力。

Abstract: Digestive tract malignancies are one of the most common malignant tumors. At present， the incidence rate and the mortality rate of gastrointestinal malignunt tumors are high， which bring more and more medical burden to the world. Therefore， it is of great significance to seek new methods of prevention and treatment. TGR5 is the first confirmed G protein-coupled bile acid receptor with a wide range of gene expression， including endocrine glands， fat cells， muscles， immune organs， spinal cord and enteric nervous system. TGR5 signaling pathway can be involved in the regulation of glucose metabolism and energy metabolism， inhibition of inflammatory reactions and regulation of cell proliferation， which may become the new target for the prevention and treatment of digestive tract tumors. This article mainly discusses the recent advances in TGR5 in metabolism， inflammatory response and cell proliferation， and describes its effects on the development of digestive tract tumors and its therapeutic potential.

丁江涛,赵培培,王富兵. 胆汁酸受体TGR5与消化道恶性肿瘤的研究进展[J]. .

DING Jiangtao,ZHAO Peipei and WANG Fubing. Research Progress of Bile Acid Receptor TGR5 and Digestive Tract Malignancies[J]. .

参考文献

[1]Chen W, Zheng R, Baade PD, et al. Cancer Statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2]Houten SM, Watanabe M, Auwer XJ, et al. Endocrine functions of bile acids[J]. EMBO J, 2006, 25(7):1419-1425.
[3]Li T, Apte U. Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer[J]. Adv Pharmacol, 2015, 74:263-302.
[4] Takahashi S, Tanaka N, Fukami T, et al. Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development[J]. Hepatol Commun, 2018, 2(12):1567-1582.
[5] Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites[J]. Cell, 1995, 81(5):687-693.
[6] Martinot E, Sedes L, Baptissart M, et al. Bile acids and their receptors [J]. Molecular Aspects of Medicine, 2017, (56):2-9.
[7] Hylemon PB, Zhou H, Pandak WM, et al. Bile acids as regulatory molecules[J]. J Lipid Res, 2009, 50(8):1509-1520.
[8] Zollner G, Wagner M, Trauner M. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol Ther, 2010, 126(3):228-243.
[9] Hong J, Behar J, Wands J, et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma[J]. Gut, 2010, 59(2): 170-180.
[10] Cao WB, Tian W, Hong J, et al. Expression of bile acid receptor TGR5 in gastric adenocarcinoma[J]. Am J Physiol Gastrointest Liver Physiol, 2013, 304(4):G322-G327.
[11] 王林,张楠,李闯等.胆酸通过其膜受体TGR5调控肝癌的发生发展[C].//中国生理学会第24届全国会员代表大会暨生理学学术大会论文集.%,2014:1-2.
[12] Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(1):55-67.
[13]Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids[J]. J Biol Chem, 2003, 278(11): 9435-9440.
[14]Hodge R, Lin J, Vasist L, et al. Safety, pharmacokinetics, and pharmacodynamic eff ects of a selective TGR5 agonist, SB?756050, in type 2 diabetes[J]. Clin Pharmacol Drug Dev, 2013, 2(3): 213?222.
[15]Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity[J]. Int J Obes (Lond), 2013, 37(12): 1553?1559.
[16]Mobraten K, Haugbro T, Karlstrom E, et al. Activation of the bile acid receptor TGR5 enhances LPS-induced inflammatory responses in a human monocytic cell line[J]. J Recept Signal Transduct Res, 2015, 35(5): 402?409.
[17]Martinot E,Sedes L,Baptissart M, et a1．Bile acids and their receptors [J]．Molecular Aspects of Medicine, 2017, 56:2-9.
[18]Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma[J]. Am J Gastroenterol, 2013, 108(2):200-207.
[19]Kahrilas PJ. The problems with surveillance of Barrett’s esophagus[J]. N Engl J Med, 2011, 365(15): 1437-1438.
[20]Si J, Fu X, Behar J, et al. NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappa B in Barrett''s esophageal adenocarcinoma cells[J]. J Biol Chem, 2007, 282:16244-16255.
[21]Shivali Marketkar, Li D, Yang DF, et al. TGR5 expression in benign, preneoplastic and neoplastic lesions of Barrett’s esophagus: Case series and findings[J]. World J Gastroenterol , 2017, 23(8): 1338-1344.
[22]Hong J, Jose Behar, Jack Wands,et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma[J]. Gut, 2010, 59(2): 170-180.
[23]Zhou Z, Xia Y, Bandla S, et al. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference[J]. Hum Pathol, 2014, 45(8):1744-1751.
[24]Pang CH, Amy LaLonde, Tony E Godfrey, et al. Bile salt receptor TGR5 is highly expressed in esophageal adenocarcinoma and precancerous lesions with significantly worse overall survival and gender differences[J]. Clinical and Experimental Gastroenterology, 2017, 10:29-37.
[25] Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk[J]. Clin Microbiol Rev, 2010, 23(4): 713-739.
[26] McClain MS, Beckett AC, Cover TL. Helicobacter pylori Vacuolating Toxin and Gastric Cancer[J]. Toxins (Basel), 2017, 9(10): E316.
[27] 张竹青,卢书明,陈美如,等.胃癌中STAT3、p-STAT3和Bcl-XL的表达及临床意义[J].肿瘤防治研究, 2014, 41(5)：121-124．
[28] Guo C, Su J, Li ZJ, et al. The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway [J]. Oncotarget, 2015, 6(33):34402-34413.
[29] Kim MA, Lee HS, Lee HE, et al. Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma[J]. Histopathology, 2009, 54(4): 442-451.
[30] Adriana Carino, Luigina Graziosi, Claudio D’Amore1,et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines[J]. Oncotarget, 2016, 7(38):61021-61035.
[31] Baptissart M, Vega A, Maqdasy S, et al. Bile acids: from digestion to cancers[J]. Biochimie, 2013, 95(3):504-517.
[32] Chen WD, Yu DN, Barry M. Forman, et al. Deficiency of G-Protein-Coupled Bile Acid Receptor Gpbar1 (TGR5) Enhances Chemically Induced Liver Carcinogenesis[J]. Hepatology, 2013, 57(2):656-666.
[33] Jansen PL. Endogenous bile acids as carcinogens[J]. J Hepatol, 2007, 47(3):434-435.
[34] He G, Karin M. NF-kappaB and STAT3: key players in liver inflammation and cancer[J]. Cell Res, 2011, 21(1):159-168.
[35] Wang YD, Chen WD, Yu D, et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice[J]. Hepatology, 2011, 54(4):1421-1432.
[36] Reich M, Klindt C, Deutschmann K, et al. Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage[J]. Dig Dis, 2017, 35(3):235-240.
[37] Reich M, Deutschmann K, Sommerfeld A, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro[J]. Gut, 2016, 65(3):487-501.
[38] Keitel V, Reich M, Reinehr R, et al. TGR5 has antiapoptotic and proliferative effects in isolated cholangiocytes and is overexpressed in human cholangiocarcinomas[A]. XXII International Bile Acid Meeting, 2012.
[39] 李艾迪. TGR5在胆管癌发生发展中的作用及机制研究[D]. 河北医科大学, 2016.
[40] De Almeida CV, de Camargo MR, Russo E,et al. Role of diet and gut microbiota on colorectal cancer immunomodulation[J]. World J Gastroenterol, 2019, 14;25(2):151-162.
[41] Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk[J]. Nutr Clin Pract, 2012, 27(5):613-623.
[42] Hofmann AF, Cravetto C, Molino G, et al. Simulation of the metabolism and enterohepatic circulation of endogenous deoxycholic acid in humans using a physiologic pharmacokinetic model for bile acid metabolism[J]. Gastroenterology, 1987, 93(4):693-709.
[43] Haslam A, Robb S.W, Hébert J.R, et al. The association between Dietary Inflammatory Index scores and the prevalence of colorectal adenoma[J]. Public Health Nutr, 2017, 20(9):1609-1616.
[44] Jensen DD, Godfrey CB, Niklas C, et al. The bile acid receptor TGR5 does not interact with beta-arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts[J]. J Biol Chem, 2013, 288(32):22942-22960.
[45] Kamada N, Seo SU, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease[J]. Nat Rev Immunol, 2013, 13(5):321-335.

快速检索引用检索图表检索高级检索